Shire plc

From Wikipedia, the free encyclopedia
Jump to: navigation, search
For other uses, see Shire (disambiguation).
Shire Plc
Type Public limited company
Traded as LSESHP, NASDAQSHPG
Industry Pharmaceuticals
Predecessors Shire Pharmaceuticals Group Plc
Founded 1986
Headquarters Registered Office: St Helier, Jersey
Corporate HQ: Dublin, Ireland
UK Operations: Basingstoke, England
Key people Matthew Emmens (Chairman)
Flemming Ørnskov, MD (CEO)
Revenue $4,934.3 million (2013)[1]
Operating income $1,733.5 million (2013)[1]
Net income $665.1 million (2013)[1]
Employees 5,300 (2014)[2]
Website www.shire.com

Shire Plc is a Jersey-registered, Irish-headquartered global specialty biopharmaceutical company.[3] Originating in the United Kingdom with a large operational base in the United States, its brands and products include Vyvanse, Adderall XR, Intuniv, Lialda, Pentasa, Fosrenol, Replagal, Elaprase, VPRIV, Firazyr and Dermagraft.

Shire has its primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It had a market capitalisation of approximately £17.1 billion as of 8 April 2014, making it the 28th-largest company on the London Stock Exchange.[4] Shire has a secondary listing on NASDAQ.

History[edit]

Shire was founded by Harry Stratford, Dr James Murray, Dennis Stephens, Peter Moriarty, and Geoff Hall in 1986.[5] It was first listed on the London Stock Exchange in 1996.[5] Shire's initial products were calcium supplements (Calcichew-D3) for patients seeking to treat or prevent osteoporosis. Shire's acquisitions include:

Date Company acquired Price Information Ref
1997 Pharmavene £105m Drug delivery [6]
1997 Richwood Pharmaceutical Company Formation of Shire-Richwood, Inc. [7]
2001 Biochem Canada [8]
2005 Transkaryotic Therapeutics [9]
2007 New River Pharmaceuticals Inc $2.3b Owners of Vyvanse [10]
2008 Jerini $521m German company focussing on hereditary angioedema [11]
2010 Movetis $565m Belgian company focussing on gastrointestinal products [12]
2011 Advanced BioHealing Regenerative medicine [13]
2012 FerroKin BioSciences $325m Biotechnology, includes acquisition of the iron chelator compound FBS0701 [14]
2013 Lotus Tissue Repair, Inc. Biotechnology, includes acquisition of ABH001 [15]
2013 Premacure AB Biotechnology [16]
2013 SARcode Bioscience Inc. Biopharmaceutical [17]
2013 ViroPharma $4.2b [18]
2014 Fibrotech $75m Antifibrotic compounds [19]
2014 Lumena $260m Rare gastro-intestinal & hepatic compounds [20]

AbbVie Takeover[edit]

On 20 June 2014, Shire rejected a takeover attempt by AbbVie. AbbVie offered £46.11 per share (£27.3 billion or $46.5 billion in total).[21] On 8 July the offer was increased to $51.5 billion.[22] On 18 July, it was announced that AbbVie would acquire Shire for $54.8 billion.[23]

Operations[edit]

Shire develops and provides healthcare in the areas of behavioural health, gastrointestinal conditions, rare diseases, and regenerative medicine.

Products[edit]

A container of Adderall XR
Name Annual revenue[1] Indication
Vyvanse $1,029.8M Attention Deficit Hyperactivity Disorder (ADHD)
Adderall XR $429.0M Attention Deficit Hyperactivity Disorder (ADHD)
Replagal $497.5M Fabry disease (lysosomal storage disorder)
Elaprase $497.6M Hunter syndrome (lysosomal storage disorder)
Lialda/Mezavant $399.9M Gastrointestinal (Ulcerative colitis)
VPRIV $306.6M Type 1 Gaucher disease
Pentasa $265.8M Gastrointestinal (Ulcerative colitis)
Intuniv $287.8M Attention Deficit Hyperactivity Disorder (ADHD)
Fosrenol $172.0M Renal disease
Dermagraft $153.8M Diabetic Foot Ulcers (“DFU”)
Firazyr $116.3M (Hereditary angioedema)
Other (including Xagrid, Equasym, and Resolor) $250.6M

In July 2014, Shire licenced the rights to the investigational Hunter sydrome compound, AGT-182, from ArmaGen for up to $225 million.[24] Shires pipeline also includes the phase II compound, SHP609, aimed at treating CNS disorders associated with Hunters syndrome.

Royalty income[edit]

Name Annual revenue[1] Indication Licensee
Adderall XR $70.3M Attention Deficit Hyperactivity Disorder (ADHD) Imapx and Teva
3TC (Lamivudine) and Zeffix (Lamivudine) $91.6M HIV and Chronic hepatitis B GlaxoSmithKline
Fosrenol $53.3M Renal disease Bayer Yakuhin
Other $26.4M

Locations[edit]

The original corporate headquarters and still major operation base are located in Basingstoke, Hampshire, England. Other major offices are located in the United States in Wayne, Pennsylvania and Cambridge, Massachusetts. In addition, Shire owns a manufacturing site in Lexington, Massachusetts and San Diego, California. It announced in November 2013 that it would be further reducing its presence in the UK.[25]

Tax Avoidance[edit]

In 2008, in reaction to new taxation measures announced by the Labour Party in the treatment of royalties on patents, the company moved its tax domicile to Dublin, Ireland.[26] Effected through the creation of a new holding company in St Helier, Jersey in the Channel Islands, it will pay reduced tax on global earnings, where royalties on patents lodged in Ireland are tax free.

Corporate leadership[edit]

The non-executive Board chairman is Susan Kilsby.[27] Flemming Ørnskov, MD, Chief Executive Officer. James Bowling, Interim Chief Financial Officer.[28]

See also[edit]

References[edit]

  1. ^ a b c d e "Preliminary Results 2013" (PDF). Retrieved 15 March 2014. 
  2. ^ "Careers". Shire plc. Retrieved 15 March 2014. 
  3. ^ "Contact Us". Shire plc. Retrieved 3 January 2010. 
  4. ^ "FTSE All-Share Index Ranking". stockchallenge.co.uk. Retrieved 30 April 2013. 
  5. ^ a b How Shire evolved
  6. ^ Shire buys US drugs delivery firm for pounds 105m The Independent, 26 February 1997
  7. ^ Investment Column: Shire focuses on buying Richwood The Independent, 5 August 1997
  8. ^ Canadians give go-ahead for Shire takeover of BioChem The Telegraph, 10 May 2001
  9. ^ U.K. drug maker agrees to buy Transkaryotic Wall Street Journal, 2005
  10. ^ Shire buys New River Pharmaceuticals for $2.6 billion Pharma Times, 21 February 2007
  11. ^ Shire to buy Jerini in $521M deal Fierce Biotech, 3 July 2008
  12. ^ Shire forges $565M buyout deal for Movetis Fierce Biotech, 3 August 2010
  13. ^ Shire swoops to buy Advanced BioHealing Pharma Times, 18 May 2011
  14. ^ Shire to buy U.S. biotech firm for up to $325 million Reuters, 15 March 2012
  15. ^ Shire Acquires Lotus Tissue Repair, Inc. Shire.com, 8 January 2013
  16. ^ Shire Acquires Premacure AB Shire.com, 12 March 2013
  17. ^ Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology Shire.com, 25 March 2013
  18. ^ Shire Buys ViroPharma for $4.2 Billion to Add Orphan Drug Bloomberg.com, 11 November 2013
  19. ^ http://www.fiercebiotech.com/press-releases/fibrotech-acquired-shire-us75m-plus-milestones
  20. ^ http://www.genengnews.com/gen-news-highlights/shire-acquires-lumena-for-260m/81249851/
  21. ^ http://www.bloomberg.com/news/2014-06-20/abbvie-offered-46-5-billion-for-shire-as-bid-rejected.html
  22. ^ http://www.bloomberg.com/news/2014-07-08/abbvie-raises-offer-for-shire-to-51-5-billion.html
  23. ^ http://www.bloomberg.com/news/2014-07-18/abbvie-to-buy-shire-for-54-8-billion-as-drug-deals-surge.html
  24. ^ http://www.genengnews.com/gen-news-highlights/armagen-licenses-agt-182-rights-to-shire-for-up-to-225m/81250142/?kwrd=Shire
  25. ^ "Shire delivers fresh blow to UK life sciences". Financial Times. 10 November 2013. Retrieved 8 December 2013. 
  26. ^ Shire moves to Ireland for tax Irish Examiner, April 2008
  27. ^ http://www.shire.com/shireplc/en/about/directors
  28. ^ http://www.shire.com/shireplc/en/about/team

External links[edit]